All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

EHA2022 abstracts: What's hot in ALL?

Jun 6, 2022
Share:

To help navigate the exciting content being presented at the EHA2022 Congress, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

Frontline and emerging therapies

P342

Baseline gene expression analysis of relapsed acute B-lymphoblastic leukemia patients treated with inotuzumab ozogamicin

P350

Blinatumomab and donor lymphocyte infusion (DLI) for molecular relapse after hematopoietic stem cell transplantation in pediatric patients

P355

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed B-cell acute lymphoblastic leukemia: updates from a phase II trial

P357

Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia (MPAL) diagnosed and treated in the last ten years. A CAMPUS-ALL study

P359

Improved overall survival and MRD clearance with blinatumomab vs chemotherapy as pre-transplant consolidation in pediatric high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL)

P368

A phase II study of inotuzumab ozogamicin for the treatment of measurable residual disease-positive B-cell acute lymphoblastic leukemia

P369

A phase II study of mini-hyper-CVD plus venetoclax in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia

P371

Hyper-CVAD with sequential blinatumomab, with or without inotuzumab ozogamicin, in adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia

S111

Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial

S113

National pegaspargase-modified risk-oriented program for Philadelphia-negative adult acute lymphoblastic leukemia/lymphoblastic lymphoma (Ph− ALL/LL). GIMEMA LAL 1913 final results

S114

Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results from a phase II study

Treatment for relapsed/refractory ALL

Real-world evidence


Biomarkers and biology

EHA2022 abstracts

To download this document, click below.

Download here

More about...